YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 144 participants.

Also called NCT06048588

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 1/2
Enrolled
  • 144 participants (enrolled count) (from the registry)
Sponsor
Beijing Inno Medicine Co., Ltd. (from the registry)
Registry
  • NCT NCT06048588
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06048588. Randomized; triple masking; primary purpose treatment. Start 2023-10-08 (actual); primary completion 2025-04-27 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis
Condition
Atherosclerotic Cardiovascular Disease
Intervention (Drug)
YN001
Intervention (Drug)
Placebo for YN001
Intervention (Drug)
rosuvastatin calcium tablets
Lead sponsor
Beijing Inno Medicine Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06048588
Content hash
ad7543c53dc4ac4fac60b00a1edaf51d453c27d92e137fd0a0b71e4358ce09ce